The U.S. FDA signed an agreement with Switzerland that will allow each country to rely on the “other’s good manufacturing practice inspections of pharmaceutical manufacturing facilities, avoiding the need for duplicate inspections.” The agreement is the result of a multi-year negotiation between the two countries. The 2012 Food and Drug Administration Safety and Innovation Act granted FDA the authority to enter into such agreements, and it already has separate agreements in place with the European Union and the United Kingdom.